Getty Images
Crocs clogs reached new heights of popularity during the pandemic as an ideal work-from-home shoe.
Crocs released its latest quarterly earnings report Thursday morning, beating analysts highest estimates and boosting its full-year forecasts.
But the manufacturer is also suing Walmart, Hobby Lobby stores and 19 other companies, alleging trademark infringement.
The ungainly but comfy Crocs clogs reached new heights of
popularity during the pandemic as not only the ideal work-from-home shoe but as
a fashion statement spotted on the feet of Justin Bieber and on the Oscar red
carpet worn by Questlove.
With that popularity, however, also came copycats that has
Fake Crocs Are Being Fought by the Maker of the Real Comfy Clogs bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
MOJAVE DESERT HOLDINGS, LLC v. CROCS, INC. Before Newman, Dyk, and O’Malley. Appeal from the Patent Trial and Appeal Board. Summary: Parties challenging.
Latest Federal Court Cases - April 2021 #3 | Schwabe, Williamson & Wyatt PC jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
Amgen Inc. v. Sanofi
, Appeal No. 2020-1074 (Fed. Cir. Feb. 11, 2021)
In this week’s Case of the Week, the Federal Circuit affirmed a district court’s JMOL ruling that asserted claims of two related pharmaceutical patents were invalid because their shared specification did not enable the full scope of the claims. The patents were directed to synthetic antibodies used in high cholesterol treatments that operate by binding to specified amino acids (or “residues”) of enzyme PCSK9, thereby blocking PCSK9 from binding to LDL cholesterol receptors (“LDLR”) and permitting those receptors to remove LDL cholesterol from the bloodstream.
The claims at issue contained dual functional limitations, requiring that a claimed antibody both bind to at least one or two of numerous listed PCSK9 residues (i.e., in ranges from one or two residues to all of them), and that the antibodies block the PCSK9/LDLR interaction. Appellee Sanofi contended that because there are millions of antibody